Evie Carchman, MD, FACS

Assistant Professor of Surgery

Dr. Carchman’s laboratory focuses on defining novel ways to prevent and treat anal cancer, which is caused by the same human papillomaviruses, such as HPV16, associated with cervical cancer and a growing fraction of head and neck cancers. They are currently examining systemic and topical therapies to treat anal dysplasia, thus preventing anal cancer development. They are also exploring targeted therapies to improve treatment responses of patients with established anal cancer. In the past 4 years they identified the important role of autophagy in preventing anal cancer development and found that, if they induce autophagy pharmacologically, they can significantly prevent anal cancer development in an HPV16 transgenic mouse model of anal cancer (Rademacher et al. J Carcinogenesis. 2018, PMID: 30123096; Rademacher et al. Virology. 2017, PMID: 28431282). In Dr. Carchman’s early career as a tenure-track, junior faculty member, she already has successfully mentored one postdoc, a general surgery resident, Dr. Brooks Rademacher, who successfully obtained his own fellowship/research grant, published several first-author manuscripts, and received several awards for his presentation/abstracts at national meetings. She has a second postdoc fellow, Jimmy McCullough, another Surgery resident, who just joined her lab. Dr. Lambert is Dr. Carchman’s senior mentor and meets with her weekly to discuss current and future research projects. Dr. Carchman collaborates with Drs. Lambert and Kimple in regard to her laboratory research studies, and collaborates with Dr. Striker in several clinical studies regarding anal dysplasia in HIV-positive patients. Dr. Carchman’s lab is supported by a $500K grant from NCI to support her lab’s efforts to develop new methods for treating patients with precancerous lesions of the anus, as well as a number of society awards. This past summer Dr. Carchman received a teaching award from the School of Medicine and Public Health